CSIMarket


Arcturus Therapeutics Holdings Inc   (ARCT)
Other Ticker:  
 


 

Arcturus Therapeutics Holdings Inc

ARCT's Financial Statements and Analysis



Arcturus Therapeutics Holdings Inc narrowed third quarter of 2023 net loss per share of $-0.61 compare to net loss per share of $-1.33 recorded in the same quarter a year ago and improved compare to net loss per share of $-1.98 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.61 $  45 Mill
$+0.72     $+32M     +237.65 %



Arcturus Therapeutics Holdings Inc 's Revenue rose by 237.65 % in third quarter of 2023 (Sep 30 2023) year on year, to $45 million and advanced by 329.13 % sequentially.


Arcturus Therapeutics Holdings Inc is Expected to report next financial results on March 27, 2024.

More on ARCT's Income Statement



Arcturus Therapeutics Holdings Inc 's in thethird quarter of 2023 recorded net loss of $-16.222 million, an improvement compare to net loss of $-35.266 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-52.550 million realized in previous quarter.

More on ARCT's Growth

Arcturus Therapeutics Holdings Inc Inventories
In Sep 30 2023 company's net cash and cash equivalents decreased by $-12 million, capital expenditures grew by -2.186-55.12%, to $-1 millions compare to same quarter a year ago

More on ARCT's Cash flow Statement


Arcturus Therapeutics Holdings Inc does not pay out common stock dividend.

In trailing twelve-month period Arcturus Therapeutics Holdings Inc earned $ 5.37 cash per share, on a free-cash flow basis 163.2 % of net earning per share.

Book value fell by -1.99 % sequentially to $10.53 per share.
Tangible Book value fell to $ 10.53 per share from $ 10.74.

Company issued 0.05 million shares or 0.20 % in Sep 30 2023.
Debt Coverage Ratio was 5.07.

More on ARCT's Dividends

 Market Capitalization (Millions) 966
 Shares Outstanding (Millions) 27
 Total Debt (Millions $) 20
 Revenue (TTM) (Millions $) 296
 Net Income (TTM) (Millions $) 99
 Cash Flow (TTM) (Millions $) 129
 Capital Exp. (TTM) (Millions $) -6
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 122




Arcturus Therapeutics Holdings Inc does not pay out common stock dividend.

In trailing twelve-month period Arcturus Therapeutics Holdings Inc had $ 5.37 cash flow per share, on a free-cash flow basis 163.2 % of net earning per share.

Book value fell by -1.99 % sequentially to $10.53 per share.
Tangible Book value fell to $ 10.53 per share from $ 10.74.

Company issued 0.05 million shares or 0.20 % in Sep 30 2023.
Debt Coverage Ratio was 5.07.

More on ARCT's Balance Sheets

 Market Capitalization (Millions) 966
 Shares Outstanding (Millions) 27
 Total Debt (Millions $) 20
 Revenue (TTM) (Millions $) 296
 Net Income (TTM) (Millions $) 99
 Cash Flow (TTM) (Millions $) 129
 Capital Exp. (TTM) (Millions $) -6
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ 122
   


  News about Arcturus Therapeutics Holdings Inc Earnings

Arcturus Therapeutics Holdings Inc Surpasses Expectations with Impressive Third Quarter 2023 Earnings Results

Arcturus Therapeutics Holdings Inc, a leading biotech company, recently announced its earnings for the third quarter ...

Arcturus Therapeutics Faces Record-Breaking Challenges in Q2 2023

Financial News Report: Major Pharmaceutical Preparations Company Reports Disastrous Q2 2023 Results
On Wednesday, Major Pharmaceutical Preparations company announced its second-quarter financial results for 2023, revealing a disastrous quarter that saw a significant decline in revenue and a widened net loss per share. The company reported a revenue decline of -61.174%, amounting to $10.52 million, compared to the same reporting period last year. Similarly, the net loss per share surged to $-1.98, indicating a significant deterioration compared to the previous year.
In contrast to Major Pharmaceutical Preparations company's poor performance, the overall sector witnessed a rise in revenue during the se...

Arcturus Therapeutics Holdings Inc Shows Positive Income Growth Amidst Various Concerns

Investors in the stock market need to approach Arcturus Therapeutics Holdings Inc with caution in light of the recent announcements. While the company achieved an impressive return on investment of 42.66% in the first quarter of 2023, this is significantly higher than its average return on investment of 3.67%. However, it is essential to note that 156 other companies in the Healthcare sector outperformed ARCT in terms of return on investment.
Additionally, the company's total ranking has deteriorated from 0 to 1578 compared to the fourth quarter of 2022, indicating a decline in performance. The decline in net income is another cause for concern, although the company has improved its return on investment ...


Date modified: 2023-11-16T18:18:21+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com